Following the reporting of some serious adverse events, in temporal concomitance with the administration of doses belonging to the batch ABV2856 of the AstraZeneca anti COVID-19 vaccine, AIFA has decided as a precaution to issue a ban on the use of this batch throughout the national territory and reserves the right to take further measures, where necessary, also in close coordination with the EMA, the agency of the European drug.
At present, no causal link has been established between the administration of the vaccine and these events.
AIFA is carrying out all the necessary checks, acquiring clinical documentation in close collaboration with the NAS and the competent authorities. The samples of this lot will be analyzed by the Istituto Superiore di Sanità.
AIFA will promptly communicate any new information that becomes available.